How has Jing Lou's remuneration changed compared to 3SBio's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2025	n/a	n/a	CN¥2b
Mar 31 2025	n/a	n/a	CN¥2b
Dec 31 2024	CN¥8m	CN¥2m	CN¥2b
Sep 30 2024	n/a	n/a	CN¥2b
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥5m	CN¥1m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	CN¥4m	CN¥1m	CN¥2b
Sep 30 2022	n/a	n/a	CN¥2b
Jun 30 2022	n/a	n/a	CN¥2b
Mar 31 2022	n/a	n/a	CN¥2b
Dec 31 2021	CN¥4m	CN¥932k	CN¥2b
Sep 30 2021	n/a	n/a	CN¥1b
Jun 30 2021	n/a	n/a	CN¥1b
Mar 31 2021	n/a	n/a	CN¥934m
Dec 31 2020	CN¥4m	CN¥432k	CN¥836m
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥194m	CN¥432k	CN¥974m
Sep 30 2019	n/a	n/a	CN¥1b
Jun 30 2019	n/a	n/a	CN¥1b
Mar 31 2019	n/a	n/a	CN¥1b
Dec 31 2018	CN¥6m	CN¥432k	CN¥1b

Compensation vs Market: Jing's total compensation ($USD1.15M) is above average for companies of similar size in the Hong Kong market ($USD835.85K).

Compensation vs Earnings: Jing's compensation has increased by more than 20% in the past year.

CEO

Jing Lou (62 yo)

19.3yrs

Tenure

CN¥8,117,000

Compensation

Dr. Jing Lou, M.D., Ph.D. is a Co-Founder of 3SBio Inc. and has been its Executive Chairman of the Board since April 1, 2012 and also serves as its Chief Executive Officer and President. Dr. Lou is Directo...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jing Lou	Co-Founder	no data	CN¥8.12m	2.36% HK$ 1.7b
Dongmei Su	Senior VP & Executive Director	no data	CN¥1.46m	1.04% HK$ 734.3m
Xiang He	Chief Financial Officer	2.4yrs	no data	no data
Siu Kuen Lai	Company Secretary	3.8yrs	no data	no data
Yanli Liu	General Manager of Sunshine Guojian Pharmaceutical (Shanghai) Co.	2.3yrs	no data	no data
Yong Xu	General Manager of Shenzhen Sciprogen Bio-pharmaceutical Technology Co.	10.9yrs	no data	no data
Zheng Jin	General Manager of Shenyang Sunshine Pharmaceutical Co.	4.9yrs	no data	no data
An Yu	General Manager of Zhejiang Sunshine Mandi Pharmaceutical Co.	4.9yrs	no data	no data
Zhao Xinyi	Executive of IR	no data	no data	no data

4.4yrs

Average Tenure

46.5yo

Average Age

Experienced Management: 1530's management team is considered experienced (4.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jing Lou	Co-Founder	19.3yrs	CN¥8.12m	2.36% HK$ 1.7b
Dongmei Su	Senior VP & Executive Director	13.5yrs	CN¥1.46m	1.04% HK$ 734.3m
Tianruo Pu	Independent Non-Executive Director	10.5yrs	CN¥274.00k	no data
Jiaoe Zhang	Non-Executive Director	1.5yrs	CN¥406.00k	0.51% HK$ 363.8m
Hoi Ti Yang	Independent Non-Executive Director	4.5yrs	CN¥274.00k	no data
Joo Yeow Ng	Independent Non-Executive Director	3.9yrs	CN¥274.00k	no data

7.5yrs

Average Tenure

58yo

Average Age

Experienced Board: 1530's board of directors are considered experienced (7.5 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/12/05 18:25
End of Day Share Price	2025/12/05 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

3SBio Inc. is covered by 36 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Bo Yu	China International Capital Corporation Limited
Zhuhong Chen	China Merchants Securities (HK) Co., Ltd
Fangqi Dai	China Merchants Securities (HK) Co., Ltd

3SBio Management

Management criteria checks 2/4

Key information

Recent management updates

The Compensation For 3SBio Inc.'s (HKG:1530) CEO Looks Deserved And Here's Why

Non-Executive Director recently sold HK$1.4m worth of stock

Non-Executive Director recently sold HK$5.7m worth of stock

3SBio Inc., Annual General Meeting, Jun 25, 2025

Co-Founder recently bought HK$1.5m worth of stock

3Sbio Inc. Announces Management Changes

Recent updates

3SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

3SBio Inc.'s (HKG:1530) Shares Climb 28% But Its Business Is Yet to Catch Up

First half 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued

Investor sentiment improves as stock rises 22%

Analysts Just Shipped A Substantial Upgrade To Their 3SBio Inc. (HKG:1530) Estimates

New major risk - Revenue and earnings growth

Estimating The Fair Value Of 3SBio Inc. (HKG:1530)

First half 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

3SBio Inc. to Report First Half, 2025 Results on Aug 29, 2025

Should You Be Adding 3SBio (HKG:1530) To Your Watchlist Today?

Consensus EPS estimates increase by 18%

3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million.

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 16%

Upcoming dividend of HK$0.25 per share

Consensus EPS estimates increase by 12%

Now 21% undervalued

There's Reason For Concern Over 3SBio Inc.'s (HKG:1530) Massive 26% Price Jump

3SBio Inc. Declares Final Dividend for the Year Ended 31 December 2024, Payable on 15 August 2025

The Compensation For 3SBio Inc.'s (HKG:1530) CEO Looks Deserved And Here's Why

Investor sentiment improves as stock rises 15%

Analysts Just Published A Bright New Outlook For 3SBio Inc.'s (HKG:1530)

Are Investors Undervaluing 3SBio Inc. (HKG:1530) By 42%?

Consensus EPS estimates increase by 22%

Investor sentiment deteriorates as stock falls 16%

Solid Earnings Reflect 3SBio's (HKG:1530) Strength As A Business

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Non-Executive Director recently sold HK$1.4m worth of stock

3SBio Inc. (HKG:1530) Stock Rockets 36% As Investors Are Less Pessimistic Than Expected

Non-Executive Director recently sold HK$5.7m worth of stock

3SBio (HKG:1530) Has Announced A Dividend Of CN¥0.25

3SBio Inc. Receives Breakthrough Therapy Designation by China's National Medical Products Administration

New minor risk - Share price stability

Investor sentiment improves as stock rises 33%

3SBio (HKG:1530) Will Pay A Dividend Of CN¥0.25

3SBio Inc. (HKG:1530) Released Earnings Last Week And Analysts Lifted Their Price Target To HK$10.80

Dividend of HK$0.25 announced

Full year 2024 earnings: EPS and revenues exceed analyst expectations

3SBio Inc., Annual General Meeting, Jun 25, 2025

Investor sentiment improves as stock rises 18%

3SBio Inc. (HKG:1530) Soars 27% But It's A Story Of Risk Vs Reward

3SBio Inc. to Report Fiscal Year 2024 Results on Mar 25, 2025

3SBio Inc. (HKG:1530) Screens Well But There Might Be A Catch

Investor sentiment deteriorates as stock falls 17%

First half 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 22%

Co-Founder recently bought HK$1.5m worth of stock

First half 2024 earnings: EPS and revenues exceed analyst expectations

3SBio Inc. to Report First Half, 2024 Results on Aug 22, 2024

Upcoming dividend of HK$0.25 per share

3Sbio Inc. Announces Management Changes

New minor risk - Dividend sustainability

3SBio Inc., Annual General Meeting, Jun 25, 2024

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Mandi Foam of 3SBio Inc. Approves for Market Launch

First half 2023 earnings: EPS and revenues exceed analyst expectations

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022)

3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market

Upcoming dividend of HK$0.10 per share at 1.3% yield

3SBio Inc., Annual General Meeting, Jun 20, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Now 22% undervalued

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director